SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
这世界折磨我
Lv1
30 积分
2023-09-15 加入
最近求助
最近应助
互助留言
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials
9天前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
12天前
已完结
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
12天前
已完结
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)
13天前
已完结
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
13天前
已完结
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
13天前
已完结
Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study
15天前
已完结
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)
7个月前
已关闭
没有进行任何应助
感谢
9天前
感谢,速度真快
12天前
感谢,帮大忙了
12天前
感谢,帮大忙了
12天前
速度真快,感谢
13天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论